Clinical Trial Update: Arsenic Trioxide, Cytarabine, and Idarubicin in Treating Patients With Acute Myeloid Leukemia [Phase 1]

View source ↗

Summary

A Phase 1 trial evaluating the combination of arsenic trioxide, cytarabine, and idarubicin in patients with acute myeloid leukemia has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Acute Myeloid Leukemia

Drugs mentioned

• Arsenic Trioxide (arsenic trioxide)
• CYTARABINE (CYTARABINE)
• Idarubicin (idarubicin)

Snippet

Sponsor: Roswell Park Cancer Institute | Conditions: Leukemia | Phase 1 | Status: COMPLETED